Literature DB >> 1310841

In situ hybridization and laryngeal papillomas.

F Rimell1, R Maisel, V Dayton.   

Abstract

The technique of in situ hybridization with biotin-labeled probes was applied to 20 patients with laryngeal papillomatosis (9 with adult-onset disease and 11 with juvenile-onset). Ten patients were noted for epithelial transformation of their laryngeal disease. All patients, regardless of their clinical outcome, tested positive for human papillomavirus group 6/11. The biotin method of in situ hybridization proved to be a sensitive method in this study, identifying the infecting viral group in 23 of 24 samples. This study also tested for group 16/18 and is the first to test for the presence of group 31/33/35 in the larynx. These viruses or members of related groups have been reported in malignancies of the head and neck as well as the uterine cervix. They have yet, however, to be identified in benign laryngeal papillomas or laryngeal papillomas that have undergone epithelial transformation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310841     DOI: 10.1177/000348949210100203

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  3 in total

1.  Laryngeal papillomatosis: molecular, histopathological, and clinical evaluation.

Authors:  N Gale; M Poljak; V Kambic; D Ferluga; J Fischinger
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

2.  Laryngeal papillomatosis: morphological study by light and electron microscopy of the HPV-6.

Authors:  Regina Helena Garcia Martins; Norimar H Dias; Elisa Aparecida Gregório; Mariângela Alencar Marques; Márcia Guimarães da Silva; João Manuel Grisi Candeias
Journal:  Braz J Otorhinolaryngol       Date:  2008 Jul-Aug

Review 3.  Recurrent respiratory papillomatosis: current and future perspectives.

Authors:  Marco Carifi; Domenico Napolitano; Morando Morandi; Danilo Dall'Olio
Journal:  Ther Clin Risk Manag       Date:  2015-05-05       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.